Four Editorial Board Members Promoted to Associate Editors at the Journal of Cancer Drug Resistance

The journal of Cancer Drug Resistance (CDR) proudly announces the promotion of four esteemed Editorial Board members, Elisa Giovannetti, Paola Perego, Chiara Riganti, and Hailin Tang, to the position of Associate Editors, following a thorough evaluation conducted by the Editor-in-Chief, Prof. Godefridus J. Peters, and the Editorial Office of the journal. Their promotion recognizes their exceptional contributions to the journal and their steadfast dedication to advancing research in the field of cancer drug resistance.

Elisa Giovannetti, affiliated with the Department of Medical Oncology at Cancer Center Amsterdam, Amsterdam University Medical Centers, and the Cancer Pharmacology Lab at Fondazione Pisana per la Scienza, has made significant strides in molecular pharmacology and research on chemoresistance. Her work has shed light on novel therapeutic approaches and targets in pancreatic cancer and thoracic cancers. Particularly groundbreaking are her studies on SF3B1 modulators and resistance mechanisms in non-small cell lung cancer. Elisa has played a pivotal role in shaping the content of CDR, particularly in the areas of targeted cancer therapy and therapy-resistant pancreatic carcinoma.

Paola Perego, from the Department of Applied Research and Technological Development at Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy, has focused her research on molecular biology and pharmacology, with a particular emphasis on understanding cisplatin resistance in ovarian cancer. Her expertise in DNA damage, apoptosis, and cytotoxicity has contributed significantly to the development of innovative strategies for overcoming drug resistance in various cancer types. Paola has been instrumental in curating Special Issues on tackling cisplatin resistance in ovarian cancer and drug resistance in melanoma since joining the CDR Editorial Board.

Chiara Riganti, associated with the Department of Oncology at the University of Torino, Italy, has made substantial contributions to the field of chemo-immunoresistant tumor models and drug resistance in lung cancer, prostate cancer, and glioblastoma multiforme. Her research has yielded valuable insights into overcoming resistance mechanisms and identifying new therapeutic targets. Chiara has played a key role in research addressing the challenges of drug resistance in glioblastoma and lung cancer since joined the CDR Editorial Board.

Hailin Tang, based at Sun Yat-sen University Cancer Center in Guangzhou, China, has directed his research towards the role of non-coding RNA in cancer drug resistance. His work has offered critical insights into the molecular mechanisms underlying tumor metastasis and metabolism, paving the way for the development of novel therapeutic strategies. Hailin, since joining the CDR Editorial Board in 2023, has already made significant contributions to Special Issues on the role of non-coding RNA in cancer drug resistance.

Prof. Godefridus J. Peters has extended his congratulations to Elisa Giovannetti, Paola Perego, Chiara Riganti and Hailin Tang on their position to Associate Editors, speaking highly of their expertise, dedication, and collaborative spirit in advancing the mission of CDR .

Once again, the Editorial Office of Cancer Drug Resistance congratulates Elisa Giovannetti, Paola Perego, Chiara Riganti, and Hailin Tang on their well-deserved promotions and expresses gratitude for their ongoing commitment to excellence in cancer research. We look forward to their continued contributions in their new roles.

For more information about Cancer Drug Resistance, please visit https://www.oaepublish.com/cdr.

Editor: Louise Pan
Language Editor: Catherine Yang
Production Editor: Yan Zhang
Respectfully submitted by the Editorial Office of Cancer Drug Resistance.